Bispecific antibodies (bsAbs) are making waves in the biotherapeutics world, especially in oncology and immunotherapy. But how can we accelerate the discovery process and pinpoint the best candidates? In this webinar, learn how Bio-Rad Laboratories SpyLock Technology is transforming bispecific antibody discovery!
In this webinar, Dr. Francisco Ylera, head of R&D at Bio-Rad Laboratories, will share how SpyLock Technology is revolutionizing bispecific antibody discovery!
You will learn:
• How SpyLock uses the SpyCatcher-SpyTag system to quickly assemble and screen hundreds of bsAbs
• Integration with Bio-Rad’s Pioneer™ Antibody Discovery Platform for high-throughput screening
• A real-world case study showcasing how SpyLock has helped identify the most promising bispecific candidates
This is a great opportunity for anyone looking to stay ahead in bispecific antibody research!
👉 Register here to secure your spot!
About speaker:
Francisco Ylera is the head of the R&D team that generated the Pioneer Antibody Discovery Platform and developed the SpyLock Technology for bispecific generation and screening. He has been with Bio-Rad for over 20 years and works on customer antibody generation projects designing the selection, antibody characterization, and method optimizations. Francisco has contributed to over 25 publications, patents and book chapters, earning more than 480 citations. Francisco holds a diploma in chemistry from RWTH Aachen University, Germany, and a Ph.D. in biochemistry from the Free University Berlin, Germany. After his Ph.D., he did a postdoc at the Harvard Institute of Medicine, Boston, USA.
Immunogenicity is a critical risk factor in the development of biologics, including monoclonal antibodies, ADCs, recombinant proteins, and cell & gene therapies. It can endanger patient safety and reduce treatment effectiveness.
This webinar will explore how the cutting-edge MAPPs (MHC-Associated Peptide Proteomics) assay, a high-sensitivity in vitro immunopeptidomics approach, can help identify regions within therapeutic proteins prone to HLA binding. By assessing sequence-based risks of activating T cell responses, the MAPPs assay plays a key role in preclinical immunogenicity risk assessments.
Key Benefits of Attending:
- Enhance lead selection and optimize candidates
- Investigate known immunogenicity challenges
- Learn from a case study about an ADC that identified immunogenicity issues early in clinical trials
- By integrating the MAPPs assay into your development pipeline, you can take a proactive approach to immunogenicity risk assessment, leading to more informed decisions in biologics development.
Speaker: Dr. Noel Smith, Head of Immunology at Lonza | noel.smith@lonza.com
Dr. Noel Smith earned his PhD at the University of Cambridge in metabolic disease and has been with Lonza since 2009. He has been instrumental in developing assays for immunogenicity and immunotoxicity risk screening and currently leads the Immunology group at Lonza.
Don’t miss the opportunity to deepen your understanding of immunogenicity risk in biologics development.
👉 Register Here and secure your spot!
Monoclonal antibody discovery has been a foundational innovation that continues to drive novel antibody therapeutics in research areas including cancer, autoimmune disease, and infectious disease. As the demands and requirements for new antibodies continue to evolve, especially around safety, efficacy, and functional characterization, more powerful screening technologies are critical to antibody discovery and therapeutic development success. Unlike hybridoma and display technologies that can limit antibody diversity, have low campaign success, and require months to perform, the Beacon® optofluidic technology enables rapid selection of lead candidates by serial function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.
This presentation will first highlight Bruker Cellular Analysis’ full Beacon antibody discovery suite for screening primary plasma cells and memory B cells, including the newest ability to discover antibody hits based on relative binding affinity, and share how customers can leverage optofluidic technology to rapidly discover high value monoclonal antibodies with the highest chances of success and fastest turnaround times.
The second half of this presentation will highlight how GenScript uses the Beacon optofluidic system for initial single B cell screening, followed by the state-of-the-art ProSpeed expression system for rapid re-expression and enabling world-class antibody characterization. Genscript’s ProSpeed™ single B cell screening service transforms lead characterization, including deep functional antibody profiling and enhanced BCR sequence recovery, making it faster and more cost effective than traditional plasmid-based expression systems.
Registration is open!
About the speakers:
Vincent Pai, Director, Product Management, Bruker Cellular Analysis
Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of experience in cell biology, nanotechnology, and microfluidics, with a background from UC San Diego and Massachusetts General Hospital in Boston. He now leads new product development for antibody discovery applications on the Beacon® optofluidic system.
Yu Liang, PhD, VP of Ab Drug Discovery, GenScript ProBio
Dr. Yu Liang received his Ph.D. degree in Virology/Microbiology from the University of Chicago and completed his postdoctoral training at NIAID, NIH. He then joined Novartis Inst. for Biomedical Research as a PI/lab head, and WuXi Biologics Discovery as Portfolio Director and Senior Project Leader. Currently he serves as VP of Ab Drug Discovery at GenScript ProBio, a global CDMO company providing end-to-end service from discovery to commercialization in cell and gene therapy (CGT), vaccine and antibody protein drug, to accelerate drug development for global customers. Dr. Liang has over 20 years of research experience in biomedical science in both academia and industry. His broad and in-depth knowledge & experience covers cellular / molecular biology, infectious diseases and molecular virology, viral/ tumor immunology and immunotherapy, and early phase drug discovery of bio-therapeutics, with special expertise in the discovery of therapeutic modalities based on therapeutic Abs (mAbs, BsAbs, ADCs, etc.).
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
Our selection of On Demand webinars can be viewed here.
Our YouTube channel includes selected webinars as well as recordings of our Symposia on topics such as:
- Computational Antibody Discovery: State of the Art
- Biopharmaceutical Informatics
- Harnessing Cytokines for Cancer Immunotherapy
- Emerging Immunotherapeutics for Ovarian Cancer Symposium
- Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells
